
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>Molecular Diversity Preservation International</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20098592</article-id><article-id pub-id-type="pmc">2810219</article-id><article-id pub-id-type="doi">10.3390/md7040483</article-id><article-id pub-id-type="publisher-id">marinedrugs-07-00483</article-id><article-categories><subj-group subj-group-type="heading"><subject>Communication</subject></subj-group></article-categories><title-group><article-title>Microarray-Based Transcriptional Profiling of Renieramycin M and Jorunnamycin C, Isolated from Thai Marine Organisms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Charupant</surname><given-names>Kornvika</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-07-00483">1</xref></contrib><contrib contrib-type="author"><name><surname>Suwanborirux</surname><given-names>Khanit</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-07-00483">1</xref><xref ref-type="corresp" rid="c1-marinedrugs-07-00483">*</xref></contrib><contrib contrib-type="author"><name><surname>Daikuhara</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-07-00483">2</xref></contrib><contrib contrib-type="author"><name><surname>Yokoya</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-07-00483">2</xref></contrib><contrib contrib-type="author"><name><surname>Ushijima-Sugano</surname><given-names>Rie</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-07-00483">3</xref></contrib><contrib contrib-type="author"><name><surname>Kawai</surname><given-names>Takatoshi</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-07-00483">3</xref></contrib><contrib contrib-type="author"><name><surname>Owa</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-07-00483">3</xref><xref ref-type="corresp" rid="c1-marinedrugs-07-00483">*</xref></contrib><contrib contrib-type="author"><name><surname>Saito</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-07-00483">2</xref><xref ref-type="corresp" rid="c1-marinedrugs-07-00483">*</xref></contrib></contrib-group><aff id="af1-marinedrugs-07-00483"><label>1</label> Department of Pharmacognocy and Pharmaceutical Botany, Center for Bioactive Natural Products from Marine Organisms and Endophytic Fungi (BNPME), Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand</aff><aff id="af2-marinedrugs-07-00483"><label>2</label> Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan</aff><aff id="af3-marinedrugs-07-00483"><label>3</label> Tsukuba Research Laboratories, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan</aff><author-notes><corresp id="c1-marinedrugs-07-00483"><label>*</label> Author to whom correspondence should be addressed; E-Mails: 
<email>skhanit@chula.ac.th</email> (K.S.); 
<email>t-owa@hhc.eisai.co.jp</email> (T.O.); 
<email>naoki@my-pharm.ac.jp</email> (N.S.); Tel./Fax: +66-2218-8357 (K.S.);Tel./Fax: +81-29-847-7614 (T.O.); Tel./Fax: +81-42-495-8794 (N.S.).</corresp></author-notes><pub-date pub-type="collection"><month>12</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>19</day><month>10</month><year>2009</year></pub-date><volume>7</volume><issue>4</issue><fpage>483</fpage><lpage>494</lpage><history><date date-type="received"><day>26</day><month>8</month><year>2009</year></date><date date-type="rev-recd"><day>14</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p>Renieramycin M and jorunnamycin C, two isoquinolinequinone compounds differing only at the C-22 ester side chain, were evaluated for their cytotoxic effects on human colon (HCT116) and breast (MDA-MB-435) cancer cell lines. These two compounds displayed potent cancer cell growth inhibition, their IC<sub>50</sub> values reaching nanomolar order. To examine their effects on transcription, we carried out oligonucleotide microarray analysis with focus on the similarities and differences between the two compounds in terms of transcriptional profiles. We found that the down-regulation of PTPRK (protein tyrosine phosphatase receptor type K) can be considered as a biomarker responsive to the cytotoxic effects of this class of antitumor marine natural products.</p></abstract><kwd-group><kwd>renieramycin M</kwd><kwd>jorunnamycin C</kwd><kwd>marine sponge</kwd><kwd>oligonucleotide microarray</kwd><kwd>antitumor agent</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><label>1.</label><title>Introduction</title><p>Tetrahydroisoquinolinequinones and their reduced forms have attracted considerable interest over the past 30 years due to their potent biological activities [<xref ref-type="bibr" rid="b1-marinedrugs-07-00483">1</xref>]. A great many such natural products have been isolated, predominantly from Actinomycetes and marine organisms. On the basis of their characteristic structures, antibiotics could be subdivided into three categories: (1) naphthyridinomycins, cyanocyclines, and bioxalomycins, (2) saframycins and safracins, and (3) quinocarcins, tetrazomine, and lemonomycin. Meanwhile, marine natural products can be subdivided into two categories: (1) renieramycin, cribrostatin, jorumycin, and jorunnamycin and (2) ecteinascidins (<xref ref-type="fig" rid="f1-marinedrugs-07-00483">Figure 1</xref>). The most bioactive member of marine natural isoquinoline family, ecteinascidin 743 (Yondelis, trabectedin), has a unique mechanism of action in that its binds to the minor groove of DNA to interfere with cell division, activated transcription, and DNA repair [<xref ref-type="bibr" rid="b2-marinedrugs-07-00483">2</xref>&#x02013;<xref ref-type="bibr" rid="b9-marinedrugs-07-00483">9</xref>]. Ecteinascidin 743 has been approved by the European Commission for use in advanced soft tissue sarcoma patients who do not respond to anthracyclines and ifosfamide, or who are unsuited to receive these agents. The remarkable results of preclinical and clinical trials of ecteinascidin 743 have stimulated further research of this class of antitumor agents, including PM00104 (Zalypsis) [<xref ref-type="bibr" rid="b10-marinedrugs-07-00483">10</xref>,<xref ref-type="bibr" rid="b11-marinedrugs-07-00483">11</xref>], phthalascidin (Pt 650) [<xref ref-type="bibr" rid="b12-marinedrugs-07-00483">12</xref>], and QAD [<xref ref-type="bibr" rid="b13-marinedrugs-07-00483">13</xref>] (<xref ref-type="fig" rid="f2-marinedrugs-07-00483">Figure 2</xref>).</p><p>Renieramycins E and F were isolated from <italic>Reniera</italic> sp. by Faulkner&#x02019;s group in 1989 [<xref ref-type="bibr" rid="b14-marinedrugs-07-00483">14</xref>,<xref ref-type="bibr" rid="b15-marinedrugs-07-00483">15</xref>]. These two compounds, whose ring system and the relative stereochemistry are identical those of saframycin A, exhibit strong cytotoxicity toward cultured cells <italic>in vitro</italic> and antitumor activity against several experimental tumors <italic>in vivo</italic>. Jorumycin, which was discovered in very minute quantities from the mantle and mucus of the Pacific nudibranch <italic>Jorunna funebris</italic>, possesses growth inhibitory activity against various human cancer cell lines [<xref ref-type="bibr" rid="b16-marinedrugs-07-00483">16</xref>]. These three compounds have a relatively unstable carbinolamine group that may decomposed during isolation process, thus, they are available in only minute quantities from natural sources.</p><p>In our search for new metabolites via the isolation and characterization of biologically active compounds from Thai marine animals, we succeeded in the isolation and structure elucidation of renieramycin M, which is a stable congener of renieramycin E with &#x003b1;-aminonitrile group instead of calbinolamine group, from the Thai sponge, <italic>Xestospongia</italic> sp., by pretreatment with potassium cyanide [<xref ref-type="bibr" rid="b17-marinedrugs-07-00483">17</xref>,<xref ref-type="bibr" rid="b18-marinedrugs-07-00483">18</xref>]. We realized the gram-scale supply of renieramycin-type compounds using our procedure, and recently reported significant results gained from the extension of our initial investigation and the results of cytotoxicity evaluation of C-22 ester analogues and a very promising compound, the 2&#x02032;-pyridinecarboxylic acid ester derivative [<xref ref-type="bibr" rid="b19-marinedrugs-07-00483">19</xref>] (<xref ref-type="fig" rid="f2-marinedrugs-07-00483">Figure 2</xref>). We also reported the isolation of jorunnamycins A&#x02013;C from the mantles, visceral organs, and egg ribbons of the Thai nudibranch <italic>Jorunna funebris,</italic> following the same procedure that used potassium cyanide [<xref ref-type="bibr" rid="b20-marinedrugs-07-00483">20</xref>].</p><p>Described herein is a significant extension of our initial investigation of renieramycin M and jorunnamycin C, cyano-group containing isoquinolinequinone ester analogues. We used oligonucleotide microarray analysis to clarify the effects of these two compounds on cellular transcription. We focused on transcriptional SAR (structure and activity relationship) studies to identify a potential gene expression marker(s) that is closely associated with the antitumor activity of these fascinating marine natural products.</p></sec><sec sec-type="results|discussion"><label>2.</label><title>Results and Discussion</title><p>Renieramycin M and jorunnamycin C were isolated from potassium cyanide pretreated sponge, <italic>Xestospongia</italic> sp., and nudibranch, <italic>Jorunna funebris</italic>, respectively. Human cancer cell lines HCT116 (colon) and MDA-MB-435 (breast) were grown in RMPI 1640 (Sigma) containing supplements that included 10% (v/v) heat-inactivated fetal bovine serum (Equitech-BIO) and a solution of 100 U/mL penicillin and 100 &#x003bc;g/mL streptomycin (Invitrogen). Cell culture was performed at 37 &#x000b0;C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air.</p><p>After continuous exposure of these compounds for three days, the concentration required for 50% growth inhibition (IC<sub>50</sub>) was determined by the MTT colorimetric assay [<xref ref-type="bibr" rid="b21-marinedrugs-07-00483">21</xref>]. The results are presented in <xref ref-type="table" rid="t1-marinedrugs-07-00483">Table 1</xref>. In this assay, renieramycin M was more potent than jorunnamycin C (by approximately twofold on IC<sub>50</sub> basis) against human HCT116 colon and MDA-MB-435 breast cancer cell lines [<xref ref-type="bibr" rid="b22-marinedrugs-07-00483">22</xref>].</p><p>In order to compare renieramycin M and jorunnamycin C on the basis of their transcriptional signatures, we analyzed the expression changes of more than 8,500 transcripts in HCT116 and MDA-MB-435 cells using Affymetrix Human Genome Focus arrays. The investigated time points were 4 h and 12 h. All data were obtained in triplicate to verify statistical significance [<xref ref-type="bibr" rid="b23-marinedrugs-07-00483">23</xref>].</p><p>The hierarchical clustering data on the dendrogram format and the cosine coefficients between any two data points on the table format are shown in <xref ref-type="fig" rid="f3-marinedrugs-07-00483">Figure 3</xref>. This analysis revealed that renieramycin M and jorunnamycin C have similar effects on the gene expression of each human cancer cell line and also at each time point (cosine coefficients: 0.66 in the 4-h treatment for HCT116; 0.57 in the 12-h treatment for HCT116; 0.74 in the 4-h treatment for MDA-MB-435; and 0.76 in the 12-h treatment for MDA-MB-435). The high correlation indicates that both compounds operate via essentially the same primary mechanism(s) of action, particularly in MDA-MB-435, a more sensitive cancer cell line to these antitumor agents.</p><p>Venn diagrams in <xref ref-type="fig" rid="f4-marinedrugs-07-00483">Figure 4</xref> present the number of genes up- and down-regulated by at least twofold with statistical significance (p-value &#x0003c; 0.05) by treatment with renieramycin M and jorunnamycin C. The obtained results are summarized as follows: (i) transcriptional down-regulation was more predominant than up-regulation for both compounds irrespective of the cell lines and the time points in general; (ii) the numbers of genes significantly altered by treatment with renieramycin M and jorunnamycin C were larger in MDA-MB-435 than in HCT116, consistent with the order of cellular sensitivity to both compounds; (iii) significant overlap was observed between the genes altered by treatment with renieramycin M and jorunnamycin C in both cell lines; and (iv) the numbers of significantly altered genes in both cell lines were larger with renieramycin M treatment than with jorunnamycin C treatment, even though the drug concentrations for this analysis were corrected by using the 2 &#x000d7; IC<sub>50</sub> values of both compounds. These observations indicate that the C-22 ester side chain structure has a profound influence on the transcriptional perturbation by the renieramycin and jorunnamycin class of antitumor marine products.</p><p><xref ref-type="fig" rid="f5-marinedrugs-07-00483">Figures 5</xref> and <xref ref-type="fig" rid="f6-marinedrugs-07-00483">6</xref> highlight the genes altered by at least twofold coordinately in HCT116 and MDA-MB-435 by 12-h treatment with renieramycin M or jorunnamycin C. The commonly up- or down-regulated genes between these two cell lines could be considered as biomarker candidates responsive to the cytotoxic effects of these compounds. In case of 12-h treatment with renieramycin M, there were 8 and 37 genes were found to be up- and down-regulated, respectively. It is note worthy that GADD45A was found to be up-regulated in three reports describing expression profiles of ecteinascidin 743 treatment cell lines, human epithelioid cervix adenocarcinoma HeLa [<xref ref-type="bibr" rid="b6-marinedrugs-07-00483">6</xref>], human lung carcinoma A549 [<xref ref-type="bibr" rid="b9-marinedrugs-07-00483">9</xref>], and HCT116 &#x00026; MDA-MB-435 [<xref ref-type="bibr" rid="b12-marinedrugs-07-00483">12</xref>]. It is known that the transcription levels of GADD45A are increased following growth arrest and DNA-damage. This result strongly suggested that renieramycin M and jorunnamycin C have the similar G2/M arrest activities of ecteinascidin 743. On the other hand, down-regulated 37 genes of renieramycin M treatment experiments were subjected to GO (Gene Ontology) analysis to examine compound-associated biological processes, cellular components, and molecular functions. As the result, the following GO terms were enriched with p-values &#x0003c; 0.05: cell division, chromosome segregation, mitosis, and microtubule cytoskeleton organization and biogenesis in biological processes; intercellular junction and tight junction in cellular components; and diacylglycerol binding, guanylate kinase activity, and lipid binding in molecular functions (<xref ref-type="fig" rid="f6-marinedrugs-07-00483">Figure 6</xref>). From this GO-biological processes analysis, it is suggested that renieramycin M may affect on mytotic phase of the cell cycle, which was also highlighted by the up-regulated GADD45A gene. GO analyses of the other set of expression level altered genes in common in both cell lines showed no significant enriched GO terms.</p><p>To select a set of biomarker genes in responsive to renieramycin M and jorunnamycin C treatments, the genes whose expression levels commonly altered in both cell lines with these two compounds were examined (<xref ref-type="fig" rid="f7-marinedrugs-07-00483">Figure 7</xref>).</p><p>Within the list of down-regulated genes in 12-h treatments with both compounds, only one gene, <italic>PTPRK</italic>, was found to satisfy the selection criteria. The down-regulation of this gene seems to be involved in the primary mechanism(s) of action of both compounds, and is therefore considered to be a potential biomarker in response to the renieramycin and jorunnamycin class of antitumor marine products. <italic>PTPRK</italic> dephosphorylates <italic>EGFR</italic> and affects the downstream <italic>Erk</italic> activity. Xu <italic>et al.</italic> reported that overexpression of this gene in human keratinocytes decreased <italic>EGFR</italic> tyrosine phosphorylation, and resulted in near complete inhibition of growth [<xref ref-type="bibr" rid="b24-marinedrugs-07-00483">24</xref>]. This result is contrary to our expectation, however, the other PTPRs effects and kinase cascade cross-talks make the biological system to be complex, and the detailed <italic>PTPRK</italic> functions are still under the investigation. Martinez <italic>et al.</italic> reported that <italic>PTPRK</italic> is down-regulated in ecteinascidin 743 sensitive human sarcoma cells, on the contrary, it is up-regulated in resistant cells [<xref ref-type="bibr" rid="b25-marinedrugs-07-00483">25</xref>]. These findings support the idea that <italic>PTPRK</italic> gene is a potentially useful expression marker to monitor the antitumor effects of not only renieramycin M and jorunnamycin M but also a variety of naturally occurring isoquinolinequinones and their reduced forms with extremely potent antitumor activity.</p></sec><sec sec-type="conclusions"><label>3.</label><title>Conclusions</title><p>We utilized oligonucleotide microarray analysis to profile the effects of renieramycin M and jorunnamycin C on cellular transcription, and found that the down-regulation of <italic>PTPRK</italic> gene can be a potentially useful biomarker in response to this class of unique antitumor marine products. The finding that renieramycin M is more potent against cancer cell growth than journnamycin C was also confirmed by the gene expression analysis, suggesting that the C-22 ester side chain structure should have a critical impact on not only the antiproliferative activity but also the transcriptional signatures of this class of unique antitumor natural products. This kind of microarray-based transcriptional SAR study represents a new and effective approach to drug discovery in the post-genomic era [<xref ref-type="bibr" rid="b26-marinedrugs-07-00483">26</xref>]. Effects to be examined of other types of cytotoxic molecules on the expression of <italic>PTPRK</italic> and compared with those of the ecteinascidin class of anticancer molecules are being made.</p></sec></body><back><ack><p>This research was partially supported by the Japan Society for the Promotion of Science (JSPS) AA Scientific Platform Program and a grant from the High-Tech Research Center Project, the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (S0801043). K. C. was sponsored by the Thailand Research Fund (TRF) for the 2003 Royal Golden Jubilee (RGJ) Ph. D. Program Scholarship (PHD/0157/2456). BNPME is supported by the Grant for Center of Excellence from the Commission on Higher Education, Thailand. We are grateful to JSPS and the National Research Cooperation of Thailand (NRCT) for supporting the collaboration between Thai and Japanese researchers in this work.</p></ack><fn-group><fn><p><italic>Samples Availability:</italic> Available from the authors.</p></fn></fn-group><ref-list><title>References and Notes</title><ref id="b1-marinedrugs-07-00483"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JD</given-names></name><name><surname>Williams</surname><given-names>RM</given-names></name></person-group><article-title>Chemistry and Biology of the Tetrahydroisoquionoline Antitumor Antibiotics</article-title><source>Chem Rev</source><year>2002</year><volume>102</volume><fpage>1669</fpage><lpage>1730</lpage><pub-id pub-id-type="pmid">11996547</pub-id></mixed-citation></ref><ref id="b2-marinedrugs-07-00483"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinehart</surname><given-names>KL</given-names></name></person-group><article-title>Antitumor Compounds from Tunicates</article-title><source>Med Drug Rev</source><year>2000</year><volume>20</volume><fpage>1</fpage><lpage>27</lpage></mixed-citation></ref><ref id="b3-marinedrugs-07-00483"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Kolb</surname><given-names>EA</given-names></name><name><surname>Gorfajn</surname><given-names>B</given-names></name><name><surname>Scotto</surname><given-names>KW</given-names></name></person-group><article-title>Ecteinascidin 743 Inhibits Activated but not Constitutive Transcription</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>3377</fpage><lpage>3381</lpage><pub-id pub-id-type="pmid">12067978</pub-id></mixed-citation></ref><ref id="b4-marinedrugs-07-00483"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takebayashi</surname><given-names>Y</given-names></name><name><surname>Pourquier</surname><given-names>P</given-names></name><name><surname>Zimonjic</surname><given-names>DB</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Emmert</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Urasaki</surname><given-names>Y</given-names></name><name><surname>Kanzaki</surname><given-names>A</given-names></name><name><surname>Akiyama</surname><given-names>S</given-names></name><name><surname>Popescu</surname><given-names>N</given-names></name><name><surname>Kraemer</surname><given-names>KH</given-names></name></person-group><article-title>Pommier, Antiproliferativity of Ecteinascidin 743 Is Dependent upon Transcription-Coupled Nucleotide-Excision Repair</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>961</fpage><lpage>966</lpage><pub-id pub-id-type="pmid">11479630</pub-id></mixed-citation></ref><ref id="b5-marinedrugs-07-00483"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aune</surname><given-names>GJ</given-names></name><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Ecteinascidin 743: A Novel Anticancer Drug with a Unique Mechanism of Action</article-title><source>Anticancer Drugs</source><year>2002</year><volume>13</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">12172500</pub-id></mixed-citation></ref><ref id="b6-marinedrugs-07-00483"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajate</surname><given-names>C</given-names></name><name><surname>An</surname><given-names>F</given-names></name><name><surname>Mollinedo</surname><given-names>F</given-names></name></person-group><article-title>Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>41580</fpage><lpage>41589</lpage><pub-id pub-id-type="pmid">12198119</pub-id></mixed-citation></ref><ref id="b7-marinedrugs-07-00483"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimeno</surname><given-names>J</given-names></name><name><surname>Faircloth</surname><given-names>G</given-names></name><name><surname>Fernandez Sousa-Faro</surname><given-names>JM</given-names></name><name><surname>Scheuer</surname><given-names>PJ</given-names></name><name><surname>Rinehart</surname><given-names>K</given-names></name></person-group><article-title>New Marine Derived Anticancer Therapeutics &#x02013; A Journey from the Sea to Clinical Trials</article-title><source>Mar Drugs</source><year>2004</year><volume>2</volume><fpage>14</fpage><lpage>29</lpage></mixed-citation></ref><ref id="b8-marinedrugs-07-00483"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fayette</surname><given-names>J</given-names></name><name><surname>Coquard</surname><given-names>IR</given-names></name><name><surname>Alberti</surname><given-names>L</given-names></name><name><surname>Ranch&#x000e8;re</surname><given-names>D</given-names></name><name><surname>Boyle</surname><given-names>H</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name></person-group><article-title>ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas</article-title><source>Oncologist</source><year>2005</year><volume>10</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">16314293</pub-id></mixed-citation></ref><ref id="b9-marinedrugs-07-00483"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David-Cordonnier</surname><given-names>M-H</given-names></name><name><surname>Gajate</surname><given-names>C</given-names></name><name><surname>Olmea</surname><given-names>O</given-names></name><name><surname>Laine</surname><given-names>W</given-names></name><name><surname>de la Iglesia-Vicente</surname><given-names>J</given-names></name><name><surname>Perez</surname><given-names>C</given-names></name><name><surname>Cuevas</surname><given-names>C</given-names></name><name><surname>Otero</surname><given-names>G</given-names></name><name><surname>Manzanares</surname><given-names>I</given-names></name><name><surname>Bailly</surname><given-names>C</given-names></name><name><surname>Mollinedo</surname><given-names>F</given-names></name></person-group><article-title>DNA and Non-DNA Targets in the Mechanism of Action of the Antitumor Drug Trabectedin</article-title><source>Chem Biol</source><year>2005</year><volume>12</volume><fpage>1201</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">16298299</pub-id></mixed-citation></ref><ref id="b10-marinedrugs-07-00483"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guirouin-Barbat</surname><given-names>J</given-names></name><name><surname>Antony</surname><given-names>S</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Zalypsis (PM00104) is a Potent Inducer of &#x003b3;-H2AX foci and Reveals the Importance of the C Ring of Trabectedin for Transcription-coupled Repair Inhibition</article-title><source>Mol Cancer Ther</source><year>2009</year><volume>8</volume><fpage>2007</fpage><lpage>2014</lpage>, also see <ext-link ext-link-type="uri" xlink:href="http://www.pharmamar.com/en/pipeline/zalypsis.cfm">http://www.pharmamar.com/en/pipeline/zalypsis.cfm</ext-link><pub-id pub-id-type="pmid">19584237</pub-id></mixed-citation></ref><ref id="b11-marinedrugs-07-00483"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>EJ</given-names></name><name><surname>Owa</surname><given-names>T</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Corey</surname><given-names>EJ</given-names></name></person-group><article-title>Phthalascidin, a Synthetic Antitumor Agent with Potency and Mode of Action Comparable to Ecteinascidin 743</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>3496</fpage><lpage>3501</lpage><pub-id pub-id-type="pmid">10097064</pub-id></mixed-citation></ref><ref id="b12-marinedrugs-07-00483"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>EJ</given-names></name><name><surname>Corey</surname><given-names>EJ</given-names></name><name><surname>Owa</surname><given-names>T</given-names></name></person-group><article-title>Antitumor Activity and Gene Expression-Based Profiling of Ecteinascidin 743 and Phthalascidin Pt 650</article-title><source>Chem Biol</source><year>2001</year><volume>8</volume><fpage>1151</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">11755394</pub-id></mixed-citation></ref><ref id="b13-marinedrugs-07-00483"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plowright</surname><given-names>AT</given-names></name><name><surname>Schaus</surname><given-names>SE</given-names></name><name><surname>Myers</surname><given-names>AG</given-names></name></person-group><article-title>Transcriptional Response Pathways in a Yeast Strain Sensitive Saframycin A and a More Potent Analog Evidence for a Common Based of Activity</article-title><source>Chem Biol</source><year>2002</year><volume>9</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">12031667</pub-id></mixed-citation></ref><ref id="b14-marinedrugs-07-00483"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>H</given-names></name><name><surname>Faulkner</surname><given-names>DJ</given-names></name></person-group><article-title>Renieramycins E and F from the Sponge <italic>Reniera</italic> sp: Reassignment of the Stereochemistry of the Renieramycins</article-title><source>J Org Chem</source><year>1989</year><volume>54</volume><fpage>5822</fpage><lpage>5824</lpage></mixed-citation></ref><ref id="b15-marinedrugs-07-00483"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frincke</surname><given-names>JM</given-names></name><name><surname>Faulkner</surname><given-names>DJ</given-names></name></person-group><article-title>Antimicrobial Metabolites of the Sponge <italic>Reniera</italic> sp</article-title><source>J Am Chem Soc</source><year>1982</year><volume>104</volume><fpage>265</fpage><lpage>269</lpage></mixed-citation></ref><ref id="b16-marinedrugs-07-00483"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Cavaliere</surname><given-names>P</given-names></name><name><surname>Wahidulla</surname><given-names>S</given-names></name><name><surname>Naik</surname><given-names>CG</given-names></name><name><surname>Cimino</surname><given-names>G</given-names></name></person-group><article-title>A New Antitumor Isoquinoline Alkaloid from the Marine Nudibranch</article-title><source>Jorunna funebris Tetrahedron</source><year>2000</year><volume>56</volume><fpage>7305</fpage><lpage>7308</lpage></mixed-citation></ref><ref id="b17-marinedrugs-07-00483"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suwanborirux</surname><given-names>K</given-names></name><name><surname>Amnuoypol</surname><given-names>S</given-names></name><name><surname>Plubrukarn</surname><given-names>A</given-names></name><name><surname>Pummangura</surname><given-names>S</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>C</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name></person-group><article-title>Chemistry of Renieramycins. Part 3. Isolation and Structure of Stabilized Renieramycin Type Derivatives Possessing Antitumor Activity from Thai Sponge, <italic>Xestospongia</italic> Species Pretreated with Potassium Cyanide</article-title><source>J Nat Prod</source><year>2003</year><volume>66</volume><fpage>1441</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">14640515</pub-id></mixed-citation></ref><ref id="b18-marinedrugs-07-00483"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amnuoypol</surname><given-names>S</given-names></name><name><surname>Suwanborirux</surname><given-names>K</given-names></name><name><surname>Pummangura</surname><given-names>S</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>C</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name></person-group><article-title>Chemistry of Renieramycins. Part 5. Structure Elucidation of Minor Components of Renieramycins O and Q-S, from Thai Marine Sponge, <italic>Xestospongia</italic> Species, Pretreated with Potassium Cyanide</article-title><source>J Nat Prod</source><year>2004</year><volume>67</volume><fpage>1023</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">15217287</pub-id></mixed-citation></ref><ref id="b19-marinedrugs-07-00483"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charupant</surname><given-names>K</given-names></name><name><surname>Daikuhara</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>E</given-names></name><name><surname>Amnuoypol</surname><given-names>S</given-names></name><name><surname>Suwanborirux</surname><given-names>K</given-names></name><name><surname>Owa</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name></person-group><article-title>Chemistry of Renieramycins. Part 8. Synthesis and Cytotoxicity Evaluation of Renieramycin M-Jorunnamycin A Analogues</article-title><source>Bioorg Med Chem</source><year>2009</year><volume>17</volume><fpage>4548</fpage><lpage>4558</lpage><pub-id pub-id-type="pmid">19457672</pub-id></mixed-citation></ref><ref id="b20-marinedrugs-07-00483"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charupant</surname><given-names>K</given-names></name><name><surname>Suwanborirux</surname><given-names>K</given-names></name><name><surname>Amnuoypol</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>E</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name></person-group><article-title>Jorunnamycins A&#x02013;C, New Stabilized Renieramycin-Type Bistetrahydroisoquinolines Isolated from the Thai Nudibranch J<italic>orunna funebris</italic></article-title><source>Chem. Pharm. Bull.</source><year>2007</year><volume>55</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">17202706</pub-id></mixed-citation></ref><ref id="b21-marinedrugs-07-00483"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T</given-names></name></person-group><article-title>Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays</article-title><source>J Immunol Methods</source><year>1983</year><volume>65</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">6606682</pub-id></mixed-citation></ref><ref id="b22-marinedrugs-07-00483"><label>22.</label><mixed-citation publication-type="other"><bold><italic>In vitro antiproliferative activity</italic></bold>: Exponentially growing cells (1,500 cells per well for HCT116 and 3,000 cells per well for MDA-MB-435) were seeded into 96-well microtiter plates and pre-cultured for one day. Both compounds (renieramycin M and jorunnamycin C) were dissolved in dimethyl sulfoxide (DMSO) to make 20 mM and further diluted with the culture medium to prepare threefold serial dilutions with the maximum concentration being 100 nM after the addition into each well. The obtained dilutions were added to the plates and incubation was continued for an additional three days. The antiproliferative activity was measured in triplicate by the MTT colorimetric assay. Absorbance was measured with a TECAN microplate reader at a test wavelength of 540 nm and a reference wavelength of 660 nm to be taken as an index of the number of viable cells. The IC<sub>50</sub> value (the concentration required to inhibit cell growth by 50%) was determined by the least squares method.</mixed-citation></ref><ref id="b23-marinedrugs-07-00483"><label>23.</label><mixed-citation publication-type="book"><bold><italic>Oligonucleotide microarray gene expression analysis</italic></bold>: HCT116 and MDA-MB-435 cells were each plated at 20 &#x000d7; 10<sup>6</sup> cells per dish in 10-cm-diameter dishes with 10 mL of fresh RPMI 1640 medium After 24 h pre-incubation, HCT116 cells were treated with 2 &#x000d7; IC<sub>50</sub> concentration of each test compound (33 nM renieramycin M or 55 nM jorunnamycin C) for 4 h and 12 h MDA-MB-453 cells were also treated with 2 &#x000d7; IC<sub>50</sub> concentration of each test compound (13 nM renieramycin M or 33 nM jorunnamycin C) for 4 h and 12 h DMSO (02%) treatment was used as control Total RNA was extracted from the cells using Trizol (Invitrogen) The extracted RNA was purified using an RNeasy kit (Qiagen) Double-stranded cDNA was synthesized from 5 &#x003bc;g of total RNA by means of a SuperScript double-stranded cDNA synthesis kit (Invitrogen) with T7-d(T)<sub>24</sub> primer The cDNA product was purified by phenol/chloroform/isoamyl alcohol extraction <italic>In vitro</italic> transcription was carried out by means of a GeneChip IVT Labeling kit (Affymetrix). The resulting biotin-labeled cRNA was purified using the RNeasy kit. cRNA was fragmented at 94 &#x000b0;C for 35 min, and then hybridized for 16 h onto an Affymetrix GeneChip Human Genome Focus array that is capable of probing approximately 8,500 transcripts. The probe arrays were washed and stained with streptavidin-phycoerythrin and biotinylated goat anti-streptavidin on an Affymetrix Fluidics Station. Fluorescence intensities were captured with a Hewlett-Packard confocal laser scanner. All quantitative data were processed using the robust multi-array average (RMA) method [27], and transcriptional signature was defined as the differences between the data for compound treatment and those for DMSO treatment (control) on a logarithmic scale. Hierarchical clustering of the obtained transcriptional signatures for all test samples was done using the unweighted pair grouping method with arithmetic mean (UPGMA) in GeneSpring software to afford a dendrogram (tree graph) based on the similarity (cosine correlation). Up- and down-regulated genes were selected according to the following criteria: i) at least twofold change compared with control data; and ii) statistical significance with p-value &#x0003c; 0.05 by the t-test in triplicate data. Gene Ontology (GO) analysis was used to illuminate compound-related biological processes, cellular components, and molecular functions. Enriched GO terms with Benjamini-Hochberg adjusted p-values &#x0003c; 0.05 were selected using the Bioconductor GOstats library [28].</mixed-citation></ref><ref id="b24-marinedrugs-07-00483"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>LJ</given-names></name><name><surname>Grachtchouk</surname><given-names>V</given-names></name><name><surname>Voorhees</surname><given-names>JJ</given-names></name><name><surname>Fisher</surname><given-names>GJ</given-names></name></person-group><article-title>Receptor-type Protein-tyrosine Phosphatse-K regulates Epidermal Growth Factor Receptor Function</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>42694</fpage><lpage>42700</lpage><pub-id pub-id-type="pmid">16263724</pub-id></mixed-citation></ref><ref id="b25-marinedrugs-07-00483"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>N</given-names></name><name><surname>S&#x000e1;nchez-Beato</surname><given-names>M</given-names></name><name><surname>Carnero</surname><given-names>A</given-names></name><name><surname>Moneo</surname><given-names>V</given-names></name><name><surname>Tercero</surname><given-names>JC</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>I</given-names></name><name><surname>Navarrete</surname><given-names>M</given-names></name><name><surname>Jimeno</surname><given-names>J</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name></person-group><article-title>Transcriptional Signature of Ecteinascidin 743 (Yondelis, Trabectedin) in Human Sarcoma Cells Explanted from Chemo-Naive Patients</article-title><source>Mol Cancer Ther</source><year>2005</year><volume>4</volume><fpage>814</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">15897246</pub-id></mixed-citation></ref><ref id="b26-marinedrugs-07-00483"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owa</surname><given-names>T</given-names></name><name><surname>Yokoi</surname><given-names>A</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Yoshimatsu</surname><given-names>K</given-names></name><name><surname>Yamori</surname><given-names>T</given-names></name><name><surname>Nagasu</surname><given-names>T</given-names></name></person-group><article-title>Array-Based Structure and Gene Expression Relationship Study of Antitumor Sulfonamide Including <italic>N</italic>-[2-(4-hydroxyphenyl)amino]3-pyridinyl]-4-methoxybenzenesulfonamide and <italic>N</italic>-(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide</article-title><source>J Med Chem</source><year>2002</year><volume>45</volume><fpage>4913</fpage><lpage>4922</lpage><pub-id pub-id-type="pmid">12383017</pub-id></mixed-citation></ref><ref id="b27-marinedrugs-07-00483"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Beazer-Barclay</surname><given-names>YD</given-names></name><name><surname>Antonellis</surname><given-names>KJ</given-names></name><name><surname>Scherf</surname><given-names>U</given-names></name></person-group><article-title>Exploration, Normalization, and Summaries of High Density Oligonucleotide Array Probe</article-title><source>Biostatistic</source><year>2003</year><volume>4</volume><fpage>249</fpage><lpage>264</lpage></mixed-citation></ref><ref id="b28-marinedrugs-07-00483"><label>28.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>R</given-names></name></person-group><article-title>Using GO for Statistical Analyses</article-title><source>Proceedings of COMPSTAT 2004 Symposium</source><year>2004</year><fpage>171</fpage><lpage>180</lpage>, also see <ext-link ext-link-type="uri" xlink:href="http://comostat2004.cuni.cz/">http://comostat2004.cuni.cz/</ext-link></mixed-citation></ref></ref-list></back><floats-group><fig id="f1-marinedrugs-07-00483" position="float"><label>Figure 1.</label><caption><p>Structures of renieramycins, jorunnamycins, and related marine natural products with significant antiproliferative activity.</p></caption><graphic xlink:href="marinedrugs-07-00483f1"/></fig><fig id="f2-marinedrugs-07-00483" position="float"><label>Figure 2.</label><caption><p>Structures of synthetic analogues maintaining significant high cytotoxicity.</p></caption><graphic xlink:href="marinedrugs-07-00483f2"/></fig><fig id="f3-marinedrugs-07-00483" position="float"><label>Figure 3.</label><caption><p>Correlation between transcriptional signatures of renieramycin M and jorunnamycin C. With respect to two human cancer cell lines (HCT116 and MDA-MB-435) and two time points (4 h and 12 h), hierarchical clustering data on the dendrogram format and cosine coefficient data on the table format are presented. Abbreviations: RM, renieramycin M; JC, jorunnamycin C; HCT, HCT116; MDA, MDA-MB-435; CC, correlation coefficient.</p></caption><graphic xlink:href="marinedrugs-07-00483f3"/></fig><fig id="f4-marinedrugs-07-00483" position="float"><label>Figure 4.</label><caption><p>Venn diagrams showing the numbers of altered genes at least two fold by treatment with renieramycin M and jorunnamycin C in HCT116 and MDA-MB-435. Abbreviations: RM, renieramycin M; JC, jorunnamycin C.</p></caption><graphic xlink:href="marinedrugs-07-00483f4"/></fig><fig id="f5-marinedrugs-07-00483" position="float"><label>Figure 5.</label><caption><p>Genes up-regulated at least two fold coordinately in HCT116 and MDA-MB-435 by 12 h treatment with renieramycin M or jorunnamycin C. Abbreviations: HCT, HCT116; MDA, MDA-MB-435.</p></caption><graphic xlink:href="marinedrugs-07-00483f5"/></fig><fig id="f6-marinedrugs-07-00483" position="float"><label>Figure 6.</label><caption><p>Genes down-regulated by at least two fold coordinately in HCT116 and MDA-MB-435 by 12 h treatment with renieramycin M or jorunnamycin C. Abbreviations: HCT, HCT116; MDA, MDA-MB-435; GO, gene ontology.</p></caption><graphic xlink:href="marinedrugs-07-00483f6a"/><graphic xlink:href="marinedrugs-07-00483f6b"/></fig><fig id="f7-marinedrugs-07-00483" position="float"><label>Figure 7.</label><caption><p>Identification of candidate biomarker genes down-regulated by at least two fold coordinately in HCT116 and MDA-MB-435 by 12 h treatments with renieramycin M and jorunnamycin C.</p></caption><graphic xlink:href="marinedrugs-07-00483f7"/></fig><table-wrap id="t1-marinedrugs-07-00483" position="float"><label>Table 1.</label><caption><p>Antiproliferative activity of renieramycin M and jorunnamycin C against HCT116 and MDA-MB-435 human cancer cell lines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="2" colspan="1"><bold>Compound</bold></th><th valign="bottom" align="center" colspan="2" rowspan="1"><bold>Human cancer cell line, IC<sub>50</sub></bold><bold>&#x000b1; SD (nM)</bold><hr/></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>HCT116 (colon)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>MDA-MB-435 (breast)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Renieramycin M</td><td valign="top" align="center" rowspan="1" colspan="1">16.4 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">6.3 &#x000b1; 0.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jorunnamycin C</td><td valign="top" align="center" rowspan="1" colspan="1">27.3 &#x000b1; 1.0</td><td valign="top" align="center" rowspan="1" colspan="1">16.3 &#x000b1; 1.3</td></tr></tbody></table></table-wrap></floats-group></article>